Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 4/20 | 0.38 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.36 |
| ▸ | GRK2 | P25098 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
| ▸ | GRK3 | P35626 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798248 | 0.82 | CTSL (0.46) | MEN1KMT2ACTSKCTSSCTSL | |
| SCHEMBL4798555 | 0.81 | CTSL (0.44) | PARP1PARP10MEN1KMT2ACTSK | |
| SCHEMBL4797902 | 0.76 | PARP1 (0.41) | PARP1PARP10MEN1KMT2APOLB | |
| SCHEMBL4800105 | 0.75 | CTSK (0.49) | CTSKCTSSCTSL | |
| SCHEMBL8689328 | 0.75 | MEN1 (0.51) | PARP1PARP10MEN1KMT2APARP14 | |
| SCHEMBL4799010 | 0.74 | CA1 (0.42) | CTSKCTSSCTSL | |
| SCHEMBL4798882 | 0.74 | CTSS (0.48) | CTSKCTSSCTSL | |
| SCHEMBL4798685 | 0.73 | CTSS (0.62) | CTSKCTSSCTSL | |
| SCHEMBL4800032 | 0.70 | CTSL (0.43) | MEN1KMT2ACTSKCTSSCTSL | |
| SCHEMBL689917 | 0.69 | PARP1 (0.58) | PARP1PARP10MEN1KMT2APARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | claimed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | PARP1 3929/4885PARP10 2040/4885MEN1 3815/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | PARP1 3929/4885PARP10 2040/4885MEN1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.